Compounds > 2-[[3-(3-oxo-1,2-benzothiazol-2-yl)phenyl]sulfonylamino]benzoic acid
Page last updated: 2024-11-10

2-[[3-(3-oxo-1,2-benzothiazol-2-yl)phenyl]sulfonylamino]benzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4089709
CHEMBL ID1333250
CHEBI ID92947

Synonyms (25)

Synonym
MLS-0315803.0001 ,
MLS001170978
smr000591034
2-[[3-(3-oxo-1,2-benzothiazol-2-yl)phenyl]sulfonylamino]benzoic acid
sr-01000801708
SR-01000801708-2
HMS1723N03
MLS002460505
HMS2912I19
BRD-K54070802-001-12-8
REGID_FOR_CID_4089709
CHEMBL1333250
cid_4089709
bdbm46036
2-[[3-(3-oxidanylidene-1,2-benzothiazol-2-yl)phenyl]sulfonylamino]benzoic acid
2-[[3-(3-keto-1,2-benzothiazol-2-yl)phenyl]sulfonylamino]benzoic acid
CHEBI:92947
Z56842611
Q27164685
nsc755616
nsc-755616
AKOS034460240
521318-69-4
2-((3-(3-oxobenzo[d]isothiazol-2(3h)-yl)phenyl)sulfonamido)benzoic acid
way-606816
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (54)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency89.12510.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.23870.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency12.58930.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency1.41250.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency7.94335.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency10.69100.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588453
WRNHomo sapiens (human)Potency11.22020.168331.2583100.0000AID651768
phosphopantetheinyl transferaseBacillus subtilisPotency1.99530.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency6.30960.031637.5844354.8130AID743255
GLS proteinHomo sapiens (human)Potency6.12650.35487.935539.8107AID624170; AID624261
TDP1 proteinHomo sapiens (human)Potency11.39030.000811.382244.6684AID686978; AID686979
TSHR proteinHomo sapiens (human)Potency23.93410.338119.046637.9330AID602292
thioredoxin glutathione reductaseSchistosoma mansoniPotency25.11890.100022.9075100.0000AID485364
hypothetical protein, conservedTrypanosoma bruceiPotency5.01190.223911.245135.4813AID624173
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency3.98110.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.25890.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency10.00000.354828.065989.1251AID504847
pyruvate kinase PKM isoform aHomo sapiens (human)Potency2.51190.04017.459031.6228AID1631; AID1634
DNA polymerase betaHomo sapiens (human)Potency89.12510.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency3.35870.168316.404067.0158AID720504
DNA polymerase eta isoform 1Homo sapiens (human)Potency50.11870.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency25.11890.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency18.84520.004611.374133.4983AID624296; AID624297
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.44670.251215.843239.8107AID504327
Guanine nucleotide-binding protein GHomo sapiens (human)Potency31.62281.995325.532750.1187AID624288
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency12.77430.060110.745337.9330AID485367; AID504636; AID504637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, RNA-directed RNA polymerase NS5Dengue virus 2 16681-PDK53IC50 (µMol)46.44002.370054.1398100.0000AID588689
MPI proteinHomo sapiens (human)IC50 (µMol)0.70700.190013.825650.1000AID1535
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonasePlasmodium bergheiIC50 (µMol)33.61330.889021.028671.5000AID504765; AID540252; AID540269
phosphomannomutase 2Homo sapiens (human)IC50 (µMol)5.15000.672034.783897.3000AID1655
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproproteinHomo sapiens (human)IC50 (µMol)100.00000.125016.260374.8000AID1056
glucose-6-phosphate 1-dehydrogenase isoform bHomo sapiens (human)IC50 (µMol)17.60008.870012.851817.8000AID504792
phosphoethanolamine/phosphocholine phosphatase isoform 1Homo sapiens (human)IC50 (µMol)0.80800.11100.57690.9410AID1666
orexin/Hypocretin receptor type 1 [Homo sapiens]Homo sapiens (human)IC50 (µMol)4.48000.46013.65397.6820AID504699; AID504701
orexin receptor type 2Homo sapiens (human)IC50 (µMol)5.12501.39003.88006.8000AID624050; AID624051
insulin-degrading enzyme isoform 1Homo sapiens (human)IC50 (µMol)2.10202.10203.00924.0540AID463220
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)9.14000.270026.3638100.0000AID504719
DNA dC->dU-editing enzyme APOBEC-3A isoform aHomo sapiens (human)IC50 (µMol)100.00001.480014.526761.2000AID504722
Phosphomannomutase 2Homo sapiens (human)IC50 (µMol)5.20005.20005.20005.2000AID1187643
Mannose-6-phosphate isomeraseHomo sapiens (human)IC50 (µMol)0.71000.71003.31756.4000AID1187642
Phosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)IC50 (µMol)0.81000.50002.13435.2000AID1187641
large T antigenBetapolyomavirus macacaeIC50 (µMol)13.22000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Skn7pSaccharomyces cerevisiae (brewer's yeast)AbsAC40_uM4.77000.66005.269618.2300AID624258
ERAP1 proteinHomo sapiens (human)AC500.73000.73006.753312.1400AID743314
FAD-linked sulfhydryl oxidase ALRHomo sapiens (human)AC500.24300.00503.212622.7870AID493248
POsterior SegregationCaenorhabditis elegansAC508.71703.298012.464924.6150AID493130
Zinc finger protein mex-5Caenorhabditis elegansAC507.89500.300031.0987106.7000AID449745
HSP40, subfamily A [Plasmodium falciparum 3D7]Plasmodium falciparum 3D7AbsAC1000_uM4.77700.12904.116911.3160AID540271
hypothetical protein CAALFM_CR05890CACandida albicans SC5314AC503.49001.550013.003854.7000AID588764
H3 histone acetyltransferaseCandida albicans SC5314AC503.49001.550013.003854.7000AID588764
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
protein glycosylationPhosphomannomutase 2Homo sapiens (human)
GDP-mannose biosynthetic processPhosphomannomutase 2Homo sapiens (human)
protein N-linked glycosylationPhosphomannomutase 2Homo sapiens (human)
mannose metabolic processPhosphomannomutase 2Homo sapiens (human)
GDP-mannose biosynthetic processMannose-6-phosphate isomeraseHomo sapiens (human)
mannose to fructose-6-phosphate catabolic processMannose-6-phosphate isomeraseHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
endochondral ossificationPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
bone mineralizationPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
regulation of bone mineralizationPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
bone mineralization involved in bone maturationPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
phosphomannomutase activityPhosphomannomutase 2Homo sapiens (human)
protein bindingPhosphomannomutase 2Homo sapiens (human)
metal ion bindingPhosphomannomutase 2Homo sapiens (human)
mannose-6-phosphate isomerase activityMannose-6-phosphate isomeraseHomo sapiens (human)
zinc ion bindingMannose-6-phosphate isomeraseHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
protein bindingPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
pyrophosphatase activityPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
metal ion bindingPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
phosphocholine phosphatase activityPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
phosphoethanolamine phosphatase activityPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
phosphatase activityPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
nucleoplasmPhosphomannomutase 2Homo sapiens (human)
cytosolPhosphomannomutase 2Homo sapiens (human)
neuronal cell bodyPhosphomannomutase 2Homo sapiens (human)
cytosolPhosphomannomutase 2Homo sapiens (human)
cytosolMannose-6-phosphate isomeraseHomo sapiens (human)
extracellular exosomeMannose-6-phosphate isomeraseHomo sapiens (human)
cytosolMannose-6-phosphate isomeraseHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
extracellular membrane-bounded organellePhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
cytosolPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
extracellular matrixPhosphoethanolamine/phosphocholine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1187641Inhibition of PHOSPHO1 phosphoethanolamine activity (unknown origin) assessed as amount of inorganic phosphate release after 30 mins2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.
AID1187642Inhibition of phosphomannose isomerase (unknown origin)2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.
AID1187643Inhibition of PMM2 (unknown origin)2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's6 (75.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-phenyl-1,2-benzisothiazol-3-(2h)-one
2-phenyl-1,2-benzisothiazol-3-(2H)-one: structure given in first source; sulfur analog of ebselen		2.110
6-fluoro-2-phenyl-1,2-benzothiazol-3-one
[no description available]		2.110benzothiazoles
2-[4-methyl-3-(1-piperidinylsulfonyl)phenyl]-1,2-benzothiazol-3-one
[no description available]		2.110sulfonamide
N,N-dimethyl-3-(3-oxo-1,2-benzothiazol-2-yl)benzenesulfonamide
[no description available]		2.110sulfonamide
2-(3-chlorophenyl)-1,2-benzothiazol-3-one
[no description available]		2.110benzothiazoles
2-(4-fluorophenyl)-1,2-benzothiazol-3-one
[no description available]		2.110benzothiazoles
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610